Internal Medicine, Endocrinology, Diabetes, & Metabolism · Ithaca, NY
NPI
1639394323
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
201 Dates Dr
Ithaca, NY, 14850
Phone (607) 257-5858
Groups this clinician bills Medicare through
Medicare paid, 2024
$51K
765 services
Medicare patients, 2024
384
Average age 72
Drug cost, 2024
$2.1M
4,502 prescriptions
Company payments, 2025
$322
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Reilly W Coch was code 99214 (office e&m - established), 360 times for 256 patients. In total Reilly W Coch billed 765 services in 11 codes, and Medicare paid $51K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-04-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 360 | 256 | $86.55 | $31K |
| 83036 Blood Count | Office | 115 | 87 | $9.52 | $1,095 |
| 95251 Test - Miscellaneous | Office | 109 | 69 | $25.40 | $2,768 |
| 99204 Office E&M - New | Office | 94 | 94 | $113.81 | $11K |
| 99213 Office E&M - Established | Office | 44 | 41 | $52.98 | $2,331 |
| 99203 Office E&M - New | Office | 19 | 19 | $72.58 | $1,379 |
By year: 2022 $39K for 561 services; 2023 $48K for 694 services; 2024 $51K for 765 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 115 | 87 | $9.52 | $1,095 |
Medicare prescription drug claims, 2024
In 2024, the drug Reilly W Coch prescribed most often to Medicare patients was Ozempic (Semaglutide), with 414 prescriptions and refills. In total Reilly W Coch wrote 4,502 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 414 | 535 | 73 | $472K |
| Glipizide Er Glipizide | 405 | 1,010 | 113 | $5,454 |
| Metformin Hcl Er Metformin Hcl | 386 | 1,005 | 118 | $4,727 |
| Levothyroxine Sodium Generic | 300 | 788 | 89 | $4,703 |
| Jardiance Empagliflozin | 280 | 579 | 74 | $314K |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | 214 | 308 | 51 | $257K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 138 | 290 | 49 | $9,672 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 117 | 217 | 39 | $22K |
| Pioglitazone Hcl Generic | 107 | 273 | 27 | $1,427 |
| Trulicity Dulaglutide | 106 | 132 | 21 | $122K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 105 | 158 | 29 | $63K |
| Farxiga Dapagliflozin Propanediol | 90 | 167 | 23 | $90K |
| Novolog Flexpen Insulin Aspart | 85 | 145 | 26 | $22K |
| Metformin Hcl Generic | 82 | 206 | 22 | $488 |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 80 | 205 | 36 | $6,141 |
Brand drugs: 2,211 claims; generic drugs: 1,842 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Reilly W Coch $322 ($322 in general payments such as food, travel and fees) from 2 companies. The largest payer was Chiesi USA, Inc. with $300.
| Company | Payments | Amount |
|---|---|---|
| Chiesi USA, Inc. | 1 | $300 |
| Abbott Laboratories ABT | 1 | $21.81 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.